Clinical Trials Browser

Phase 2/3 × Neoplasm, Residual × Cytarabine × Clear all

NCT07537257 2026-04-17

VEN+IDAC vs IDAC in AML

Phase 2/3 Enrolling by invitation

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT00795756 2014-10-22

Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia

Phase 2/3 Completed

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma